Company / Return on Equity (ROE)
NEUROONE MEDICAL TECHNOLOGIES Corp Return on Equity (ROE) History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-1498.5%
FY2025
5-year range
-1498.5% / -104.1%
FY2022-FY2025
Trend
-689.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
NEUROONE MEDICAL TECHNOLOGIES Corp reports negative total equity of -1498.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-1498.5% in FY2025 with a 3-year CAGR of -1346.7%.
Declined from -104.1% to -1498.5% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -1346.7pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 689.7% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -1498.5% | -689.7% |
| FY2024 | -189.8% | -82.3% |
| FY2023 | -104.1% | +31.4% |
| FY2022 | -151.8% | - |
| FY2021 | - | - |
| FY2016 | - | - |
| FY2015 | - | - |
| FY2014 | - | - |
| FY2012 | - | - |
| FY2011 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026